Lantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels

Data presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium Demonstrate Potential Benefits of Piflufolastat F 18 Decision Making on Treatment Plans

Reno, Nevada (UroToday.com) -- Lantheus Holdings, Inc., a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, presented piflufolastat F 18 data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place February 16-18, 2023, in San Francisco, CA.

Piflufolastat F 18 is a PSMA-targeted radiopharmaceutical approved in the US for imaging prostate cancer patients both at the time of initial staging and at disease recurrence. In this study, researchers sought to evaluate the clinical utility of piflufolastat F 18 scanning in men with very low/low PSA levels (< 0.5 ng/mL).

“PYLARIFY has the potential to contribute meaningful and actionable information that can be used to personalize treatment plans in men with low PSA levels,” said Dr. Frederic Pouliot, Hospitalier Universitaire (CHU) de Québec-Université Laval. “The data we presented at ASCO GU emphasize the clinical utility of piflufolastat F 18 to assess the relevance and applicability of intended treatment management plans.”
“We had observed in the CONDOR Phase 3 study of men with biochemically recurrent (BCR) prostate cancer, that nearly two-thirds of patients had their treatment plan altered, attributed to learnings from the scan itself,” said Jean-Claude Provost, MD, Chief Medical Officer, Lantheus. “These data in the subset of men with low PSA levels reinforces the impact and potential role of piflufolastat F 18 in informing patient management decisions in real-world scenarios.”

A summary of the data presented follows:

  • In patients with PSA levels below 0.5 ng/mL, changes in intended management occurred in 39.1 percent of cases.
  • In 74.1 percent (20/27) of patients with a reported change in management, the initial intended treatment was intensified as a result of the scan images.
  • This analysis supports the clinical utility of piflufolastat F18 PET/CT in men with low PSA levels (0.2ng/mL – 0.5 ng/mL)
The abstract, “Changes in planned disease management after piflufolastat F 18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: a secondary analysis from the CONDOR study,” is available on meetinglibrary.asco.org.

Source: Lantheus Holdings, Inc. 2023. Lantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels [Press release]. https://investor.lantheus.com/news-releases/news-release-details/lantheus-presents-data-reinforcing-real-world-clinical-utility.